IONIS PHARMACEUTICALS INC 8-K

What Happened
Ionis Pharmaceuticals, Inc. filed a Form 8-K on January 12, 2026 (Item 2.02) announcing preliminary U.S. net product sales for TRYNGOLZA® of $105 million for 2025. The company furnished a press release (Exhibit 99.1) with this announcement and said the figures are unaudited and subject to adjustment ahead of its complete financial results due in February 2026.

Key Details

• Announcement date: January 12, 2026 (Form 8-K filed).
• Preliminary 2025 U.S. net product sales for TRYNGOLZA®: $105 million.
• Results are unaudited and provided as an approximation; final results to be released with full financials in February 2026.
• Press release accompanying the filing is furnished as Exhibit 99.1.

Why It Matters
This disclosure gives investors an early look at TRYNGOLZA®’s U.S. sales performance for 2025 ahead of the company’s full financial release. Preliminary product sales figures can influence near-term market expectations for Ionis’ revenue and inform investor decisions, but they are not final—investors should wait for the audited, complete results in February 2026 for definitive figures.